Teva Pharmaceutical (TEVA) Misses Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Canaccord Genuity Downgrades Teva Pharma (TEVA) to Hold
February 8, 2013 7:17 AM ESTCanaccord Genuity downgraded Teva Pharma (NYSE: TEVA) from Buy to Hold with a price target of $45.00 (from $50.00) following Q4 results.
For an analyst ratings summary and ratings history on Teva Pharma... More



